Ruxolitinib is a selective Janus-activated tyrosine kinases inhibitor (JAK1 and JAK2), available in oral (Jakafi™) and topical (Opzelura™) formulations.
It is used to treat myelofibrosis, graft-versus-host disease, and in dermatology, atopic dermatitis, and non-segmental vitiligo.
Keywords
[
{
"isarchived": false,
"websiteid": "67d80df6831394c7bcdc231a",
"_kid": "67f3c8567c465bb1d1977db2",
"createdon": "2025-04-07T12:43:02.005Z",
"updatedon": "2025-04-07T12:43:02.005Z",
"_parentClassName": "product",
"_propertyName": "keywords",
"_parentClassId": "67f3c855332ac162dbbc4eb2",
"description": "nonsegmental vitiligo",
"url": null
},
{
"isarchived": false,
"websiteid": "67d80df6831394c7bcdc231a",
"_kid": "67f3c8567c465bb1d1977db1",
"createdon": "2025-04-07T12:43:02.005Z",
"updatedon": "2025-04-07T12:43:02.005Z",
"_parentClassName": "product",
"_propertyName": "keywords",
"_parentClassId": "67f3c855332ac162dbbc4eb2",
"description": "oral jakafi",
"url": null
},
{
"isarchived": false,
"websiteid": "67d80df6831394c7bcdc231a",
"_kid": "67f3c8567c465bb1d1977db0",
"createdon": "2025-04-07T12:43:02.005Z",
"updatedon": "2025-04-07T12:43:02.005Z",
"_parentClassName": "product",
"_propertyName": "keywords",
"_parentClassId": "67f3c855332ac162dbbc4eb2",
"description": "dermatology atopic dermatitis",
"url": null
},
{
"isarchived": false,
"websiteid": "67d80df6831394c7bcdc231a",
"_kid": "67f3c8567c465bb1d1977daf",
"createdon": "2025-04-07T12:43:02.005Z",
"updatedon": "2025-04-07T12:43:02.005Z",
"_parentClassName": "product",
"_propertyName": "keywords",
"_parentClassId": "67f3c855332ac162dbbc4eb2",
"description": "topical opzelura formulations",
"url": null
},
{
"isarchived": false,
"websiteid": "67d80df6831394c7bcdc231a",
"_kid": "67f3c8567c465bb1d1977dae",
"createdon": "2025-04-07T12:43:02.005Z",
"updatedon": "2025-04-07T12:43:02.005Z",
"_parentClassName": "product",
"_propertyName": "keywords",
"_parentClassId": "67f3c855332ac162dbbc4eb2",
"description": "ruxolitinib cream ruxolitinib",
"url": null
}
]